3 European Penny Stocks With Market Caps Larger Than €1M

The European market has experienced a significant downturn, with the pan-European STOXX Europe 600 Index suffering its largest drop in five years due to heightened U.S. trade tariffs. Despite these challenges, investors may still find opportunities by exploring lesser-known segments of the market such as penny stocks. While the term 'penny stock' might seem outdated, these often smaller or newer companies can offer unique investment prospects when they possess solid financials and growth potential.

Top 10 Penny Stocks In Europe

Click here to see the full list of 437 stocks from our European Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Valora Effekten Handel (DB:VEH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Valora Effekten Handel AG is a securities trading company based in Germany with a market cap of approximately €1.70 million.

Operations: Revenue Segments: No specific revenue segments have been reported for Valora Effekten Handel AG.

Market Cap: €1.7M

Valora Effekten Handel AG, with a market cap of approximately €1.70 million, is a pre-revenue company generating less than US$1m in revenue (€504K). Despite being debt-free and having short-term assets (€1.4M) exceeding both short-term (€81.6K) and long-term liabilities (€219.5K), the company remains unprofitable with increasing losses over five years at 46.6% annually. However, it maintains a sufficient cash runway for over three years due to positive free cash flow despite shrinking by 34.3% per year. Recent earnings reported a net loss of €0.343 million for 2024, up from €0.184 million in the previous year.

• Click here to discover the nuances of Valora Effekten Handel with our detailed analytical financial health report.
• Understand Valora Effekten Handel's track record by examining our performance history report.

Nordic Financials (OB:NOFIN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nordic Financials ASA is an energy company specializing in solar power and renewable energy businesses across Europe, with a market cap of NOK8.92 million.

Operations: No revenue segments are reported for this company.

Market Cap: NOK8.92M

Nordic Financials ASA, with a market cap of NOK 8.92 million, operates in the solar power sector but remains pre-revenue, generating less than US$1m. Despite its unprofitability and high share price volatility, the company benefits from being debt-free and having no long-term liabilities. It has a sufficient cash runway for over three years due to positive free cash flow growth of 7.7% annually. Recent developments include a NOK 10 million equity offering through preference shares at NOK 0.01 each, which may support its financial stability amidst ongoing net losses reported at EUR 1.67 million for the full year ending December 2024.

• Click here and access our complete financial health analysis report to understand the dynamics of Nordic Financials.
• Learn about Nordic Financials' historical performance here.

CombiGene (OM:COMBI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: CombiGene AB (publ) is a Swedish company focused on developing gene therapy for severe life-altering diseases, with a market cap of SEK47.92 million.

Operations: The company generates revenue of SEK3.6 million from its biotechnology startup segment.

Market Cap: SEK47.92M

CombiGene AB, with a market cap of SEK47.92 million, is a pre-revenue biotech firm focused on gene therapy. The company reported a net loss of SEK44.88 million for 2024, with sales dropping to SEK0.326 million from SEK5.54 million the previous year. Despite its unprofitability and declining earnings over five years, CombiGene remains debt-free and has sufficient cash runway for two years if free cash flow trends continue. Recent strategic shifts include discontinuing the epilepsy project CG01 and terminating its agreement with Zyneyro due to financing challenges, leaving it without obligations in the pain program sector.

• Dive into the specifics of CombiGene here with our thorough balance sheet health report.
• Explore historical data to track CombiGene's performance over time in our past results report.

Where To Now?

• Gain an insight into the universe of 437 European Penny Stocks by clicking here.
• Looking For Alternative Opportunities? Outshine the giants: these 23 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com